Dr Hurvitz discusses the HER2CLIMB and HER2CLIMB-02 trials examining tucatinib's activity and safety in patients with HER2-positive metastatic breast cancer.
Tucatinib plus letrozole and palbociclib was well-tolerated and active in patients with HR and HER2-positive metastatic breast cancer, according to interim data presented at the SABCS Annual Meeting.
Mattea Reinisch, MD, highlights the final efficacy and safety results of the phase 3b, multi-center, open-label Ribecca trial for women with ER+, HER2- locally advanced or metastatic breast cancer,…
Julie Gralow, MD, Clinical Director at the Seattle Cancer Care Alliance, discusses findings from the SWOG S0307 trial.
Poorni Manohar, MD, discusses the promising potential of FES-PET imaging for detecting metastatic lobular breast cancer, especially with bone involvement.
Julie Gralow, MD, Clinical Director, Seattle Cancer Care Alliance, discusses ways that healthcare providers can encourage patient enrollment in cancer clinical trials.
Michelle Melisko, MD, discusses the background, benefits, and future potential of the DigniCap Scalp Cooling System.
Hannah Linden, MD, FACP, spoke about the use of FES and FDG PET imaging to identify bone metastases in patients with metastatic breast cancer.
Stay in the know.
OncNet Newsletter